The global contract research organisation (CRO) market is expected to expand quickly and grow at about 10.6% CAGR from 2023 to 2028. Amidst such ongoing trends, Veeda Clinical Research is coming soon to the Indian share market.
While CLSA India, IIFL Capital Services, Axis Capital, and SBI Capital are managing the Veeda Clinical Research IPO, MUFG Intime is registering it. Check out the Veeda Clinical Research IPO allotment status.
Check out the Veeda Clinical Research DRHP for more details on the Veeda Clinical Research IPO price, date, and size.
Note: 50% shares will be unlocked 30 days after allotment, while the rest will be free from lock-in restrictions after 90 days.
Check out all the major details of Veeda Clinical Research Ltd given below:
Check these insights about IPO date, size, and Veeda Clinical Research share price NSE.
For the Veeda Clinical Research IPO, the DRHP was filed with SEBI on February 7, 2025, and the company got the approval on July 3, 2025. However, there are no details given in its DRHP about the IPO dates and the Veeda Clinical Research IPO price today.
Here are the risks and strengths one should know before applying to Veeda Clinical Research Ltd:
Trusted by Clients Worldwide: The company works with over 436 clients across the globe, building long-term relationships through quality research.
Have Regulatory Approvals: With 119 successful inspections from top agencies like the FDA, WHO, and EMA, the company has proven that it meets global standards.
Global Experience: Behind the company’s success is a talented team of scientists and professionals who bring deep industry knowledge.
End-to-End Research Services: The company offers early clinical trials, bioavailability studies, and pre-clinical testing.
Risks
Rely on Large Clients: A big part of the company’s income comes from just a few top clients. Losing even one could make a noticeable difference.
Delays or Cancellations Can Hurt: If any large projects get delayed or cancelled, it could slow down growth or affect earnings.
Strict Industry Rules: The company works under tough regulations from agencies like the FDA and the European Medicines Agency.
Reputation Depends on Quality: Delivering high-quality work is key. If projects don’t meet client expectations or contract terms, it might lead to penalties.
As of October 29, 2025, the Veeda Clinical Research IPO GMP hasn’t been updated yet. You can still check live GMP trends and the subscription status numbers. For a better picture, go through the Veeda Clinical Research DRHP before you click on Apply Now.
1. How is the Veeda Clinical Research IPO review?
Veeda Clinical Research Limited is a contract research organisation. However, the IPO date, size, and Veeda Clinical Research share price NSE are still unknown. For the latest updates, you can also look for the GMP updates and check the Veeda Clinical Research news.
2. What is the Veeda Clinical Research IPO date?
The IPO open and close dates of Veeda Clinical Research IPO are unavailable as of 29 October 2025. Live subscription details can be monitored through FinnPick. You can also check Veeda Clinical Research's valuation.
3. What is the Veeda Clinical Research Energy pre IPO share price?
The Veeda Clinical Research Limited share price is not out as of 29 October 2025. Also, don't forget to check Veeda Clinical IPO news.
4. Should I use a demat account to bid for the Veeda Clinical Research Limited IPO?
Yes, a demat account is required to bid for the Veeda Clinical Research Limited IPO. Click here to get the ultimate list of the top demat account providers.
